

PROGRAM

9th European Scientific Oncology Conference



Latest Advances on Anticancer Drugs in Clinical Development

Marbella, Spain, November 3rd- 4th, 2016

www.esocmarbella.com

• CHAIRMEN

Dr. Hernán Cortés Funes, Hospital Universitario 12 de Octubre, Madrid, Spain

Dr. Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain

Dr. José Antonio López-Martín, Hospital Universitario 12 de Octubre, Madrid, Spain

Organized by:



Under the label of:



9th European Scientific Oncology Conference

Latest Advances on
Anticancer Drugs in
Clinical Development

9th

European Scientific Oncology Conference



Marbella, Spain, November 3rd- 4th, 2016

WELCOME

*We are pleased to welcome you to the **9th European Scientific Oncology Conference (ESOC-9)**, which will be held in Marbella, on November 3rd- 4th 2016.*

Since 2.000, we have met every two years in Marbella, in order to analyse and discuss all the new promising anticancer agents in the latest pre-clinical stages or already in Phase I or II clinical studies.

One more year we have invited the most relevant clinical investigators working on the field of new drug development which will actively participate in a comprehensive Scientific Program, with Keynote Lectures from experts and Sessions devoted to the presentation and discussion of individual data from different clinical research groups.

The ESOC Conference is not only an excellent opportunity to learn more about new developments, but it also offers attendees a remarkable forum for discussions, debates and controversies. It will also permit us to meet our colleagues and to enjoy the beautiful city of Marbella.

Thank you for being here with us. We wish you a pleasant and fruitful stay in Marbella!

H. Cortés-Funes

Luis Paz-Ares

J. A. López Martín

Chairmen



Latest Advances on Anticancer Drugs in Clinical Development

CHAIRMEN

Hernán Cortés-Funes, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

Luis Paz-Ares, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

José Antonio López Martín, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

SCIENTIFIC COMMITTEE

Alex A. Adjei, *Mayo Clinic, Rochester, USA*

Richard Baird, *Cambridge Cancer Centre, UK*

Hilary Calvert, *University of Newcastle, Newcastle, UK*

Hernán Cortés-Funes, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

Johann de Bono, *The Institute of Cancer Research, The Royal Marsden, London, UK*

José Antonio López Martín, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

Luis Paz-Ares, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

Eric Raymond, *Swiss Cancer Center-CHUV, Lausanne, Switzerland*

Jan Schellens, *Netherlands Cancer Institute, Amsterdam, The Netherlands*

Jean Charles Soria, *Insittut Gustave Roussy, Villejuif, France*

Anthony Tolcher, *South Texas Accelerated Research Therapeutics, LLC-START, San Antonio, Texas, USA*

FACULTY

Alex A. Adjei, *Mayo Clinic, Rochester, USA*

Richard Baird, *Cambridge Cancer Centre, UK*

Emiliano Calvo, *Centro Integral Oncológico Hospital Clara Campal, Madrid, Spain*

Amancio Carnero, *Hospital Universitario Virgen del Rocío, Sevilla, Spain*

Manuel Cobo, *Hospital Universitario Málaga General, Málaga, Spain*

Hernán Cortés-Funes, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

Jesús Corral, *Hospital Universitario Virgen del Rocío, Sevilla, Spain*

9th

European Scientific Oncology Conference



Marbella, Spain, November 3rd- 4th, 2016

Ignacio Durán, *Hospital Universitario Virgen del Rocío, Sevilla, Spain*

Alejo Efeyan, *Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain*

Sandrine Faivre, *Hôpital Beaujon, Clichy, France*

Antonio Gualberto, *Kura Oncology, Cambridge, Massachusetts, USA*

Vicente Guillem, *Instituto Valenciano de Oncología, Valencia, Spain*

Payal Kapur, *UT Southwestern Medical Center, Dallas, USA*

Christophe Le Tourneau, *Institut Curie, Paris Saclay University, Paris, France*

Spiros Linardopoulos, *The Institute of Cancer Research, London, UK*

Rafael López, *Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain*

José Antonio López Martín, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

Marcos Malumbres, *Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain*

Christophe Massard, *Institut Gustave Roussy, Villejuif, France*

Ignacio Melero, *Clinica Universitaria de Pamplona, Spain*

Gabriel Otero, *Biotech, London, UK*

Luis Paz-Ares, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*

Héctor Peinado, *Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain*

José Luis Pérez Gracia, *Clínica Universitaria de Navarra, Pamplona, Spain*

Guiseppe Portella, *Università Federico II, Napoli, Italy*

Alfonso Quintás-Cardama, *Novartis AG, New Jersey, USA*

Miguel Ángel Quintela, *Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain*

Eric Raymond, *Saint Joseph Hospital Group, Paris, France*

Antonio Rueda, *Hospital Costa del Sol, Malaga, Spain*

José María Saro, *Roche Scientific Innovation Center Zurich, Switzerland*

Laureano Simón, *Oncomatryx, Bilbao, Spain*

Laura Soucek, *Hospital Universitario Vall d'Hebron, Barcelona, Spain*

José Manuel Trigo, *Hospital Universitario Virgen de la Victoria, Málaga*

Jon Zugazagoitia, *Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain*



Latest Advances on Anticancer Drugs in Clinical Development

Thursday, November 3rd 2016

9:15 am **Welcome and Introduction**

Hernán Cortés-Funes (Madrid, Spain)

Luis Paz-Ares (Madrid, Spain)

José Antonio López Martín (Madrid, Spain)

9:30 - 11:15 am

SESSION 1: IMMUNE AGENTS I

Sponsored by    Bristol-Myers Squibb

Chairman: José Antonio López Martín (Madrid, Spain)

9:30 am **Anti PD1 Inhibitors: For every patient or only for BMK+ patients?**

Luis Paz-Ares (Madrid, Spain)

9:50 am **Biomarkers in Immunotherapy**

José Luis Pérez Gracia (Pamplona, Spain)

10:10 am **Oncolytic viruses as immunotherapeutic agents, new opportunities for rare cancer with unmet therapeutic needs?**

Guisepppe Portella (Naples, Italy)

10:30 am **Discussion**

10:50 am **Coffee break**

11:15 - 1:00 pm

SESSION 2: IMMUNE AGENTS II

Sponsored by  Bristol-Myers Squibb

Chairmen: Guisepppe Portella (Naples, Italy), Luis Paz-Ares (Madrid, Spain)

11:15 am **IDO Inhibitors**

José Antonio López Martín (Madrid, Spain)

11:35 am **Immuno-stimulating agents**

Ignacio Melero (Pamplona, Spain)

11:55 am **T Cell Bi-specific Monoclonal Antibodies**

José María Saro (Zurich, Switzerland)

12:15 pm **CARTCs in solid tumors**

Alfonso Quintás-Cardama (New Jersey, USA)

12:35 pm **Discussion**

1:00 pm **Lunch**

2:00 - 4:00 pm

SESSION 3: ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND OTHER NOVEL THERAPIES

Chairmen: Rafael López (Santiago de Compostela, Spain), Gabriel Otero (London, UK)

2:00 pm Rationale and constructions

Gabriel Otero (London, UK)

2:20 pm Novel HER2-targeting approaches for breast cáncer

Richard Baird (Cambridge, UK)

2:40 pm ADC antiPTK7

Emiliano Calvo (Madrid, Spain)

3:00 pm Targeting the tumor microenvironment with ADCs

Laureano Simón (Bilbao, Spain)

3:30 pm Discussion

3:40 pm Coffee-break

4:00 - 5:40 pm

SESSION 4: NOVEL TKIS

Chairmen: José Manuel Trigo (Malaga, Spain), Jesús Corral (Sevilla, Spain)

4:00 pm Third generation EGFR TKIs and resistance

Jesús Corral (Sevilla, Spain)

4:20 pm Novel Generation ALK Inhibitors

Jon Zugazagoitia (Madrid, Spain)

4:40 pm ROS/TKR/ RET Inhibitors

Luis Paz-Ares (Madrid, Spain)

5:00 pm Strategies to enhance CNS penetration of systemic therapies

Richard Baird (Cambridge, UK)

5:20 pm Discussion

5:40 pm Adjourn

7:15 pm Bus departure for Cocktail at HC Marbella

Cocktail

10:00 pm Return to hotel Andalucía Plaza



Latest Advances on Anticancer Drugs in Clinical Development

Friday, November 4th 2016

9:00 - 10:40 am

SESSION 5: MET INHIBITION

Chairmen: Sandrine Faivre (Clichy, France), Antonio Rueda (Malaga, Spain)

9:00 am MET/HGF relevance for targeted therapy malignancies

Eric Raymond (Paris, France)

9:20 am MET in resistance to TKI

José Manuel Trigo (Málaga, Spain)

9:40 am MET inhibition in hepatobiliary tract tumors

Sandrine Faivre (Clichy, France)

10:00 am MET amplification and MET exon 14 mutations

Emiliano Calvo (Madrid, Spain)

10:20 am Discussion

10:40 am Coffee break

11:00 am Keynote Lecture

Chairman: H, Cortes-Funes (Madrid, Spain)

Drug Development in the era of targeted therapy and immunotherapy

Alex Adjei (Rochester, USA)

11:30 - 1:30 pm

SESSION 6: TARGETING DIFFICULT TARGETS I

Chairmen: José Luis Pérez Gracia (Pamplona, Spain), Spiros Linardopoulos (London, UK)

11:30 am Targeting the RAS-ERK pathway

Antonio Gualberto (Cambridge, USA)

11:50 am Ras Family

Alex Adjei (Rochester USA)

12:10 pm Targeting MYC by a new generation of cell penetrating peptides

Laura Soucek (Barcelona, Spain)

12:30 pm CDK inhibitors

Marcos Malumbres (Madrid, Spain)

12:50 pm Discussion**1:10 pm Lunch****2:10 - 3.30 pm****SESSION 7: TARGETING DIFFICULT TARGETS II**

Chairmen: Manuel Cobo (Málaga, Spain), Marcos Malumbres (Madrid, Spain)

2:10 pm Targeting tumor suppressor genes

Amancio Carnero (Sevilla, Spain)

2:30 pm MPS1/TTK inhibition: A Novel Approach in Breast Cancer Treatment

Spiros Linardopoulos (London, UK)

2:50 pm BET inhibitors

Eric Raymond (Paris, France)

3:10 pm Discussion**3:30 - 5:10 pm****SESSION 8: PRECISION ONCOLOGY MEDICINE**

Chairmen: Vicente Guillem (Valencia, Spain), Luis Paz-Ares (Madrid, Spain)

3:30 pm How to choose a platform and the best gene panel?

Christophe Le Tourneau (Paris, France)

3:50 pm Circulating exosomes, towards the future of liquid biopsy

Héctor Peinado (Madrid, Spain)

4:10 pm Do we need a molecular tumor board?

Christophe Massard (Villejuif, France)

4:30 pm Round table discussion:

Hernán Cortés-Funes (Madrid, Spain)

Christophe Le Tourneau (Paris, France)

Héctor Peinado (Madrid, Spain)

Christophe Massard (Villejuif, France)

4:50 pm Coffee break



Latest Advances on Anticancer Drugs in Clinical Development

5:10 - 6:30 pm

SESSION 9: HYPOXIA AND METABOLISM

Chairmen: Miguel Ángel Quintela (Madrid, Spain), Ignacio Durán (Sevilla, Spain)

5:10 pm Beyond Rapamycin-Nutrient signalling in cancer

Alejo Efeyan (Madrid, Spain)

5:30 pm Novel HIF2 inhibitors

Payal Kapur (Dallas, Texas)


5:50 pm Hypoxia in Cancer Therapy

Amancio Carnero (Sevilla, Spain)

6:10 pm Discussion

6:30 pm CLOSING REMARKS

Hernán Cortés-Funes (Madrid, Spain)



“ *Comprometidos en acelerar
la transición desde la investigación
a la práctica clínica.* ”

—David Kaufman, MD, PhD
Director, MSD Oncology Clinical Research

Merck Sharp & Dohme de España, S.A. C/ Josefa Valcárcel, 38 · 28027 Madrid. www.msd.es
Copyright © 2015 Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc.,
Kenilworth, NJ, USA. Todos los derechos reservados.
ONCO-1165414-0007 (Creado: Noviembre 2015)





Latest Advances on Anticancer Drugs in Clinical Development

GENERAL INFORMATION

VENUE

Hotel Andalucía Plaza ****

Urb. Nueva Andalucía s/n

E-29660 Puerto Banús, Marbella, Spain

Web: www.hotelh10andaluciaplaza.com

CONFERENCE SECRETARIAT

BN&Co. Congress and Event Management

Paseo de la Castellana 179 - Entreplanta

28046 MADRID - Spain

Phone : +34 91 571 93 90 | +34 91 571 92 10

Fax : +34 91 571 92 06

E-mail: c.lazaro@bnyco.com

Web: www.bnyco.com



BN&Co.

Congress & Events
Management

ACCREDITATION

The Conference has applied for the Accreditation on Continuing Education Activities of Health Professions.

Once the accreditation is approved, a certificate will be delivered to all the participants. The attendance to all sessions is mandatory in order to receive the corresponding certificate.

REGISTRATION

Onsite Registration fee is 450€ (taxes included)

Onsite Registration for Physicians in Training is 200€ (taxes included)

9th

European Scientific Oncology Conference



Marbella, Spain, November 3rd - 4th, 2016

LANGUAGE

The official language of the Symposium is English. There will be no simultaneous interpretation.

INSURANCE

The organisers will not be responsible for individual, medical, travel or personal insurance. Participants are advised to take out their own personal insurance policies.

NO SMOKING

Smoking will be forbidden in all Conference areas.

MOBILE PHONES

Mobile phones must be disconnected during all the sessions.



Latest Advances on Anticancer Drugs in Clinical Development

SPONSORS

AMGEN[®]

 **astellas**
Leading Light for Life

AstraZeneca 

 **Boehringer
Ingelheim**

 **Bristol-Myers Squibb**

 **Celgene**

 **Eisai**

Janssen 
PHARMACEUTICAL COMPANIES
OF **Johnson & Johnson**

Lilly

MERCK

 **MSD**

 **NOVARTIS**

Pfizer

 **Roche**

9th European Scientific Oncology Conference

Latest Advances on
Anticancer Drugs in
Clinical Development

Marbella, Spain, November 3rd- 4th, 2016

www.esocmarbella.com

Conference Secretariat:

BN&Co. Congress and Event Management

Paseo de la Castellana 179 - entreplanta, 28046 Madrid

Tel. + 34 91 571 93 90 • E-mail: c.lazaro@bnyco.com